Another tyrosine kinase member of the EGFR family, HER2, which is usually overexpressed in specific breast cancer subtypes and in some HCC, among other solid tumors [78,79], has also been targeted with novel LYTACs. This evidence concerns the gene EGFR and hepatocellular carcinoma.